Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Research output: Contribution to journalReview article

32 Scopus citations


Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.


ASJC Scopus subject areas

  • Hematology

Cite this